$NVO has shown strong growth, and I'm bullish. With all the volatility out there, I have comfort in medical care companies - doesn't seem like medical needs will go away anytime soon. Novo is a Danish drugmaker and a leader in diabetes medicine, which is the clear growth driver for them. The company is also moving into obesity treatment, with FDA approving their new drug, Wegovy, in June. That should be promising. Historical EPS growth looks solid (6.2%/yr last five years).

What's your take?
post media
I'm always nervous when it comes to med companies. They're one FDA decision away from total chaos, but definitely lots of money to be made.

What do you think of $MRNA?
View 4 more comments
Next
Commonstock is a social network that amplifies the knowledge of the best investors, verified by actual track records for signal over noise. Community members can link their existing brokerage accounts and share their real time portfolio, performance and trades (by percent only, dollar amounts never shared). Commonstock is not a brokerage, but a social layer on top of existing brokerages helping to create more engaged and informed investors.